Efficacy and Safety of the Tx360® Nasal Applicator for Transnasal Sphenopalatine Ganglion Block
Diseases of the Nervous System | Men's Health | Women's Health
What is the purpose of this trial?
To be considered for participation in this research study, you must have a history of chronic migraine headaches. We will be testing a new treatment which may help your migraine headaches not to hurt as much, and may prevent the number of times you have migraine headaches each month. This treatment involves a drug called bupivacaine, which is an anesthetic and a plastic medical device, called Tx360®. Bupivacaine and Tx360® are both commercially available.
Total study duration for each subject is 20 weeks including a 28-day screening/baseline phase, a four week treatment phase, and 3 month follow-up phase.
- Ages18 years - 65 years
- Trial withTian Medical
- Start Date05/29/2018
- End Date12/30/2018
- Last Updated08/19/2018
- Study HIC#2000022129